Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Total Debt: 2022-2025

Historic Total Debt for NewAmsterdam Pharma Co N.V (NAMS) over the last 2 years, with Sep 2025 value amounting to $44.4 million.

  • NewAmsterdam Pharma Co N.V's Total Debt rose 134.70% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 134.70%. This contributed to the annual value of $37.5 million for FY2024, which is 198.35% up from last year.
  • According to the latest figures from Q3 2025, NewAmsterdam Pharma Co N.V's Total Debt is $44.4 million, which was up 111.93% from $20.9 million recorded in Q2 2025.
  • NewAmsterdam Pharma Co N.V's 5-year Total Debt high stood at $44.4 million for Q3 2025, and its period low was $7,727 during Q2 2023.
  • Moreover, its 3-year median value for Total Debt was $23.5 million (2025), whereas its average is $23.8 million.
  • In the last 5 years, NewAmsterdam Pharma Co N.V's Total Debt soared by 304,610.75% in 2024 and then fell by 28.85% in 2025.
  • NewAmsterdam Pharma Co N.V's Total Debt (Quarterly) stood at $4.1 million in 2022, then skyrocketed by 203.21% to $12.6 million in 2023, then spiked by 198.35% to $37.5 million in 2024, then surged by 134.70% to $44.4 million in 2025.
  • Its Total Debt stands at $44.4 million for Q3 2025, versus $20.9 million for Q2 2025 and $23.5 million for Q1 2025.